Cинтез, гіпоглікемічна активність та гостра токсичність нових імідазол-тіазолідинових гібридних структур

• Дата: 2016
• Автори: Chornous, V. O., Melnyk, O. Ya., Hliebov, O. M., Tykhonenko, M. V., Sheremeta, L. M., Yarosh, O. K., Denysenko, O. M., Rodik, R. V., Vovk, M. V.
• Формат: Стаття
• Мова: Ukrainian
• Опубліковано: National University of Pharmacy 2016
• Теми: 4-хлоро-5-формілімідазоли; 1; 3-тіазолідин-4-он; імідазол-тіазолідинові структури; синтез; гіпоглікемічна активність; гостра токсичність; УДК 547.781.4 547.789 615.012; 547.79
• Онлайн доступ: https://ophcj.nuph.edu.ua/article/view/ophcj.16.872
• Назва журналу: Journal of Organic and Pharmaceutical Chemistry

The article presents a brief description of diabetes type 2 as a disease related with carbohydrate metabolism disorder mainly caused by insulin resistance and relative insulin defi ciency. It has been noted that pathologies may appear under the action of drugs of the glitazone group; it is a major cause for systematic search for new bioactive and safe compounds with the hypoglycemic action. Considering the wide range of the biological activity of imidazole derivatives and 1,3-thiazolidine the synthesis of new hybrid structures – 5-[(1-aryl-4-chloro-1H-imidazole-5-yl)methylene]-1,3-thiazolidine-2,4-diones and their exohydrated analogues – 5-[(1-aryl-4-chloro-1H-imidazole-5-yl)methyl]-1,3-thiazolidine-2,4-diones has been carried out. A preparative suitable scheme for their obtaining has been proposed, it is based on condensation of available 1-aryl-4-chloro-5-formylimidazoles with1,3-thiazolidine-4-one and further hydrogenation of the exocyclic ylidene bond formed. The results of biomedical studies of the compounds obtained in the doses of 100, 10 and 1 mg/kg have shown that they have a strong hypoglycemic activity, which exceeds the effect of test drug pioglitazone by 55%. The acute toxicity (LD50) of 5-{[1-(4-tolyl)-4chloro-1H-imidazole-5-yl]methylene}-1,3-thiazolidine-2,4-dione is 1292.92 mg/k when injected intraperitoneally.